{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:12:22Z","timestamp":1793833942273,"version":"4.6.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2025JJ60162"],"award-info":[{"award-number":["2025JJ60162"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22374045"],"award-info":[{"award-number":["22374045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20233"],"award-info":[{"award-number":["U23A20233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303186"],"award-info":[{"award-number":["82303186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019091","name":"Key Research and Development Program of Hunan Province of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Innovation"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.xinn.2026.101274","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:25:50Z","timestamp":1769012750000},"page":"101274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["HBV-driven expansion of CXCR6+-exhausted T cells and CXCL16+ macrophage interaction: Implications for immunotherapy in HCC"],"prefix":"10.1016","volume":"7","author":[{"given":"Ranzhiqiang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzhao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuqin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianhong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-3922","authenticated-orcid":false,"given":"Sulai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xinn.2026.101274_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xinn.2026.101274_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2026.101274_bib3","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(21)02138-3","article-title":"Late presentation of hepatocellular carcinoma highlights the need for a public health programme to eliminate hepatitis B","volume":"398","author":"Nhlane","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2026.101274_bib4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41577-023-00884-8","article-title":"Localization, tissue biology and T cell state - implications for cancer immunotherapy","volume":"23","author":"Schenkel","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xinn.2026.101274_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ccell.2022.02.017","article-title":"Expanding the immunotherapy roadmap for hepatocellular carcinoma","volume":"40","author":"Baretti","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xinn.2026.101274_bib6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xinn.2026.101274_bib7","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2026.101274_bib8","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","article-title":"Enhancing anti-tumour efficacy with immunotherapy combinations","volume":"397","author":"Meric-Bernstam","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2026.101274_bib9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2026.101274_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101274_bib11","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1097\/HEP.0000000000000494","article-title":"Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma","volume":"78","author":"Lim","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.xinn.2026.101274_bib12","article-title":"Immunotherapy of hepatocellular carcinoma: recent progress and new strategy","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2026.101274_bib13","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3748\/wjg.v29.i15.2261","article-title":"Immunotherapy for recurrent hepatocellular carcinoma","volume":"29","author":"Bhatt","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.xinn.2026.101274_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jhep.2022.01.017","article-title":"Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection","volume":"77","author":"Jachs","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xinn.2026.101274_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jgh3.12737","article-title":"Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection","volume":"6","author":"Nakabori","year":"2022","journal-title":"JGH Open"},{"key":"10.1016\/j.xinn.2026.101274_bib16","article-title":"Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus","volume":"6","author":"Bonilla","year":"2020","journal-title":"Hepatoma Res."},{"key":"10.1016\/j.xinn.2026.101274_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5009\/gnl17233","article-title":"Immunotherapy for Chronic Hepatitis B Virus Infection","volume":"12","author":"Bertoletti","year":"2018","journal-title":"Gut Liver"},{"key":"10.1016\/j.xinn.2026.101274_bib18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/cpdd.317","article-title":"Cure Strategies for Hepatitis B Virus: The Promise of Immunotherapy","volume":"6","author":"Shire","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.xinn.2026.101274_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101274_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S1470-2045(21)00651-3","article-title":"Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study","volume":"23","author":"Reig","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xinn.2026.101274_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xinn.2026.101274_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000534446","article-title":"Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection Exhibited Favorable Survival from Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"13","author":"Du","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.xinn.2026.101274_bib63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s44178-025-00179-z","article-title":"Factors influencing the timing of second-line therapy for the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis. Holist","volume":"4","author":"Zhang","year":"2025","journal-title":"Integ. Oncol."},{"key":"10.1016\/j.xinn.2026.101274_bib23","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s42003-025-08443-8","article-title":"Viral-Track integrated single-cell RNA-sequencing reveals HBV lymphotropism and immunosuppressive microenvironment in HBV-associated hepatocellular carcinoma","volume":"8","author":"Liu","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xinn.2026.101274_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103302","article-title":"FDX1 downregulation activates mitophagy and the PI3K\/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production","volume":"75","author":"Sun","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.xinn.2026.101274_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","article-title":"Liver tumour immune microenvironment subtypes and neutrophil heterogeneity","volume":"612","author":"Xue","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101274_bib26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8(+) T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xinn.2026.101274_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add1016","article-title":"Multiomics and spatial mapping characterizes human CD8(+) T cell states in cancer","volume":"15","author":"Naulaerts","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xinn.2026.101274_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1498579","article-title":"CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer","volume":"14","author":"Lu","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xinn.2026.101274_bib29","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xinn.2026.101274_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-023-06733-x","article-title":"Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer","volume":"624","author":"Zhou","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101274_bib31","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41586-024-07630-7","article-title":"A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection","volume":"631","author":"Bosch","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101274_bib32","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy","volume":"78","author":"Liu","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xinn.2026.101274_bib33","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xinn.2026.101274_bib34","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/gutjnl-2018-317959","article-title":"HBV antiviral immunity: not all CD8 T cells are born equal","volume":"68","author":"Bertoletti","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.xinn.2026.101274_bib35","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2024.05.029","article-title":"Intrahepatic immunity to hepatitis B virus","volume":"81","author":"Venzin","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xinn.2026.101274_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xinn.2026.101274_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xinn.2026.101274_bib38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2019.09.031","article-title":"CXCL13-mediated recruitment of intrahepatic CXCR5(+)CD8(+) T cells favors viral control in chronic HBV infection","volume":"72","author":"Li","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xinn.2026.101274_bib39","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/gutjnl-2022-327202","article-title":"Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro","volume":"72","author":"Rossi","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.xinn.2026.101274_bib40","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/s12967-024-05681-y","article-title":"Differential T-cell profiles determined by Hepatitis B surface antigen decrease among people with Human Immunodeficiency Virus\/Hepatitis B Virus coinfection on treatment","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.xinn.2026.101274_bib41","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xinn.2026.101274_bib42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101274_bib43","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2024.09.044","article-title":"CXCL12(+) tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma","volume":"82","author":"Lu","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xinn.2026.101274_bib44","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xinn.2026.101274_bib45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xinn.2026.101274_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau6905","article-title":"Multifactorial heterogeneity of virus-specific T cells and association with the progression of human chronic hepatitis B infection","volume":"4","author":"Cheng","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xinn.2026.101274_bib47","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2009.04.045","article-title":"Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma","volume":"137","author":"Gehring","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xinn.2026.101274_bib48","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.xinn.2026.101274_bib49","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13046-023-02710-4","article-title":"Single-cell analysis reveals HBV-specific PD-1(+)CD8(+) TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients","volume":"42","author":"Liu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xinn.2026.101274_bib50","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/HEP.0000000000000369","article-title":"Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC","volume":"78","author":"You","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.xinn.2026.101274_bib51","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.hbpd.2025.04.007","article-title":"The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease","volume":"24","author":"Li","year":"2025","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.xinn.2026.101274_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217774","article-title":"Glycolytic enzyme PFKFB4 governs lipolysis by promoting de novo lipogenesis to drive the progression of hepatocellular carcinoma","volume":"626","author":"Zhou","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xinn.2026.101274_bib53","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1016\/j.cell.2021.07.015","article-title":"CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment","volume":"184","author":"Di","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101274_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1022136","article-title":"CXCR6 expressing T cells: Functions and role in the control of tumors","volume":"13","author":"Mabrouk","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2026.101274_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003100","article-title":"CXCR6 is required for antitumor efficacy of intratumoral CD8(+) T cell","volume":"9","author":"Wang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xinn.2026.101274_bib56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41420-023-01356-7","article-title":"Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy","volume":"9","author":"Zheng","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xinn.2026.101274_bib57","article-title":"Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy","volume":"9","author":"Chen","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xinn.2026.101274_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202200389","article-title":"Hybrid-Membrane-Decorated Prussian Blue for Effective Cancer Immunotherapy via Tumor-Associated Macrophages Polarization and Hypoxia Relief","volume":"34","author":"Hou","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.xinn.2026.101274_bib59","article-title":"T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2026.101274_bib60","article-title":"Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2026.101274_bib61","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1038\/s41467-024-51096-0","article-title":"ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4(+) macrophage infiltration","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101274_bib62","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5582\/bst.2025.01233","article-title":"Chinese multicenter expert consensus on the diagnosis and treatment of hilar cholangiocarcinoma: 2025 edition","volume":"19","author":"Liu","year":"2025","journal-title":"Biosci. Trends"}],"container-title":["The Innovation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666675826000214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666675826000214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:29:24Z","timestamp":1781296164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666675826000214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2666675826000214"],"URL":"https:\/\/doi.org\/10.1016\/j.xinn.2026.101274","relation":{},"ISSN":["2666-6758"],"issn-type":[{"value":"2666-6758","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HBV-driven expansion of CXCR6+-exhausted T cells and CXCL16+ macrophage interaction: Implications for immunotherapy in HCC","name":"articletitle","label":"Article Title"},{"value":"The Innovation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xinn.2026.101274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Youth Innovation Co., Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101274"}}